|
01 Jun 2025 |
Clean Science
|
Consensus Share Price Target
|
1549.20 |
1455.40 |
- |
-6.05 |
buy
|
|
|
|
|
23 May 2025
|
Clean Science
|
IDBI Capital
|
1549.20
|
1641.00
|
1433.20
(8.09%)
|
5.93 |
Buy
|
|
|
|
|
22 May 2025
|
Clean Science
|
Prabhudas Lilladhar
|
1549.20
|
1354.00
|
1328.90
(16.58%)
|
Target met |
Hold
|
|
|
reflecting a 15.9% YoY increase and a 9.5% QoQ growth. The top-line expansion of HALS rose significantly to 1,900tn in FY25 from 600tn in FY24, with a blended realization of Rs425/kg. Management has guided for HALS volumes to reach 4,500tn in FY26, with realizations expected to improve to Rs495...
|
|
08 Nov 2024
|
Clean Science
|
IDBI Capital
|
1549.20
|
1500.00
|
1479.75
(4.69%)
|
Target met |
Hold
|
|
|
|
|
07 Nov 2024
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1430.00
|
1483.60
(4.42%)
|
Target met |
Neutral
|
|
|
Clean Science (CLEAN)’s reported EBITDA in 2QFY25 was below our estimate at INR897m (+20% YoY), with a gross margin of 62.4% (vs. 65.9% in 2QFY24).
|
|
07 Nov 2024
|
Clean Science
|
Prabhudas Lilladhar
|
1549.20
|
1526.00
|
1483.60
(4.42%)
|
Target met |
Hold
|
|
|
|
|
08 Oct 2024
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1580.00
|
1541.30
(0.51%)
|
Target met |
Neutral
|
|
|
CLEAN’s R&D, focused on innovation and sustainability, achieved key milestones in FY24, including the commercialization of HALS series and the development of pharma intermediates.
|
|
21 Sep 2024
|
Clean Science
|
Prabhudas Lilladhar
|
1549.20
|
1477.00
|
1548.10
(0.07%)
|
Target met |
Hold
|
|
|
|
|
16 Sep 2024
|
Clean Science
|
Monarch Networth Capital Limited
|
1549.20
|
1750.00
|
1590.40
(-2.59%)
|
12.96 |
Accumulate
|
|
|
|
|
07 Aug 2024
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1440.00
|
1589.25
(-2.52%)
|
Target met |
Neutral
|
|
|
CLEAN’s reported EBITDA in 1QFY25 was below our estimate at INR947m (+24% YoY), with a gross margin of 65.4%.
|
|
02 Aug 2024
|
Clean Science
|
IDBI Capital
|
1549.20
|
1500.00
|
1649.80
(-6.10%)
|
Target met |
Hold
|
|
|
|
|
16 May 2024
|
Clean Science
|
ICICI Securities Limited
|
1549.20
|
1350.00
|
1350.25
(14.73%)
|
Target met |
Hold
|
|
|
Clean Science’s Q4FY24 EBITDA dipped 10% YoY to INR 945mn; EBITDA margin contracted 295bp QoQ at 41.5%. EBITDA margin delivery has been impressive, considering pricing environment remains unfavourable.
|
|
16 May 2024
|
Clean Science
|
IDBI Capital
|
1549.20
|
1425.00
|
1350.25
(14.73%)
|
Target met |
Hold
|
|
|
|
|
05 Feb 2024
|
Clean Science
|
IDBI Capital
|
1549.20
|
1425.00
|
1400.00
(10.66%)
|
Target met |
Hold
|
|
|
|
|
18 May 2023
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1380.00
|
1506.35
(2.84%)
|
Target met |
Neutral
|
|
|
|
|
21 Mar 2023
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1345.00
|
1352.75
(14.52%)
|
Target met |
Neutral
|
|
|
|
|
03 Feb 2023
|
Clean Science
|
ICICI Securities Limited
|
1549.20
|
1525.00
|
1481.90
(4.54%)
|
Target met |
Hold
|
|
|
Clean Science and Technology’s (Clean Science) Q3FY23 EBITDA margin at 45.6% was up 620bps QoQ as the company benefited from lower raw material prices, while it has not reduced realisation for key products, including MEHQ.
|
|
02 Feb 2023
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1379.00
|
1481.90
(4.54%)
|
Target met |
Neutral
|
|
|
|
|
21 Oct 2022
|
Clean Science
|
ICICI Securities Limited
|
1549.20
|
1540.00
|
1613.50
(-3.99%)
|
Target met |
Hold
|
|
|
Clean Science and Technology’s (Clean Science) Q2FY23 EBITDA margin at 39.4% was up only 40bps QoQ despite softening raw material costs due to drop in PBQ prices.
|
|
19 Aug 2022
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1660.00
|
1704.00
(-9.08%)
|
Target met |
Neutral
|
|
|
|
|
27 Jul 2022
|
Clean Science
|
Motilal Oswal
|
1549.20
|
1659.00
|
1699.25
(-8.83%)
|
Target met |
Neutral
|
|
|
|